8-K: Traws Pharma Files IND for Influenza Drug, Updates COVID-19 Study

Traws Pharma filed a U.S. IND for tivoxavir marboxil for influenza and reported positive interim results for ratutrelvir in COVID-19 patients.

Summary

• A U.S. Investigational New Drug (IND) application was filed with the FDA for tivoxavir marboxil (TXM), a potential best-in-class CAP-dependent endonuclease inhibitor, for the treatment of influenza.
• The TXM IND filing is a final step for formal consideration by the Center for Biomedical Advanced Research and Development Authority (BARDA) for inclusion in the strategic national stockpile.
• Updated interim results were announced from an ongoing randomized, open-label Phase 2 clinical study of ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor, for mild-to-moderate COVID-19.
• Ratutrelvir demonstrated a differentiated clinical profile compared to PAXLOVID, including in PAXLOVID-ineligible patients.
• Full study enrollment of 90 patients is expected in January 2026, with 95% already enrolled.
• Ratutrelvir-treated patients showed numerically superior time-to-sustained symptom alleviation and resolution (12 days) compared to PAXLOVID-treated patients (14 days, p<0.014).
• No COVID-19 symptom or virologic rebound events have been observed in ratutrelvir-treated patients to date, while one rebound event occurred in the PAXLOVID comparator arm.
• Ratutrelvir was well tolerated with fewer reported adverse events; mild dyspepsia was reported in 2 patients (7.6%) in the ratutrelvir arm, compared to 4 patients (30%) in the PAXLOVID arm who reported adverse events like dysgeusia, dizziness, and dyspepsia.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical data for ratutrelvir, showing superiority over PAXLOVID in key metrics like symptom resolution and adverse events, and addresses an unmet need for PAXLOVID-ineligible patients. The IND filing for tivoxavir marboxil is a significant regulatory step with potential for government stockpiling. These are substantial advancements for a clinical-stage biopharmaceutical company.

Positives

• IND filing for tivoxavir marboxil (TXM) for influenza, positioning it for potential inclusion in the strategic national stockpile.
• TXM is a potential best-in-class, single oral tablet, pan-influenza strain therapeutic with potent activity against H5N1 bird flu.
• Ratutrelvir demonstrated numerically superior time-to-sustained symptom alleviation (12 days) compared to PAXLOVID (14 days, p<0.014).
• No viral rebound events observed in ratutrelvir-treated patients, contrasting with one event in the PAXLOVID arm.
• Favorable tolerability profile for ratutrelvir with significantly fewer adverse events (7.6% mild dyspepsia) compared to PAXLOVID (30% adverse events including dysgeusia, dizziness, dyspepsia).
• Ratutrelvir is effective in PAXLOVID-ineligible patients, addressing a significant unmet medical need.
• Ratutrelvir is a ritonavir-free treatment, avoiding drug-drug interactions associated with ritonavir-boosted regimens.
• Ratutrelvir's pharmacokinetic profile maintains target blood plasma levels approximately 13 times above the EC50, potentially reducing rebound and Long COVID risk.
• The ratutrelvir Phase 2 study is 95% enrolled, with full enrollment expected in January 2026, indicating rapid progress.

Risks

• Substantial risks and uncertainties are involved with forward-looking statements, and actual results may differ from expectations.
• The outcome of the IND filing with the FDA is uncertain.
• The success and timing of clinical trials, including when the final analysis of the Phase 2 studies of ratutrelvir will be reported, are not guaranteed.
• The potential efficacy of ratutrelvir for COVID-19, including its ability to reduce the risk of COVID rebound and Long COVID, requires further confirmation.
• There is no guarantee that ratutrelvir will gain market acceptance or become the new standard of care if regulatory approval is obtained.
• Interactions with the FDA, BARDA, and similar foreign regulators may not always be favorable or timely.
• Market conditions, regulatory requirements, and pathways for approval can change and impact development.
• The Company's cash projections and ability to raise additional capital when needed are subject to various factors.
• The extent of the spread and threat of bird flu remains a significant variable.

Future Outlook

Traws Pharma remains optimistic about the potential inclusion of tivoxavir marboxil in the nation's armamentarium against future disease outbreaks. The interim data for ratutrelvir encourages and supports its continued clinical evaluation in acute COVID-19 and in studies designed to better understand its potential impact on longer-term outcomes, including the reduction of post-acute sequelae of SARS-CoV-2 infection (Long COVID). Full enrollment for the ratutrelvir Phase 2 study is expected in January 2026.

Management Comments

• "This filing represents an important step towards formal consideration of TXM for influenza therapy and inclusion in the strategic national stockpile." C. David Pauza, PhD, Chief Scientific Officer.
• "Coupled with our ongoing positive interactions with the U.S. Department of Health and Human Services (HHS) regarding the unique properties of TXM as a broad pan-influenza strain therapeutic, we remain optimistic about the potential inclusion of this agent in the nations armamentarium against potential future disease outbreaks." C. David Pauza, PhD, Chief Scientific Officer.
• "The favorable tolerability profile, together with a shortened time to symptom resolution and the absence of viral rebound events in ratutrelvir-treated patients, encourages and supports the continued clinical evaluation of ratutrelvir in both acute COVID-19 and in studies designed to better understand its potential impact on longer-term outcomes." Robert R. Redfield, MD, Chief Medical Officer.
• "The combination of early and sustained symptom improvement, extended dosing duration, absence of viral rebound observed to date, and favorable tolerability supports the strategic hypothesis that ratutrelvir may have utility in reducing post-acute sequelae of SARS-CoV-2 infection (Long COVID)." Dr. Redfield.
• "By enabling earlier and potentially more complete viral clearance, without the limitations associated with ritonavir boosting, ratutrelvir may offer a differentiated approach to both acute COVID-19 treatment and prevention of longer-term complications, pending confirmation in dedicated clinical studies." Dr. Redfield.
• "Collectively, the interim data position ratutrelvir as a next-generation oral 3CL protease inhibitor with ritonavir-free administration, once-daily oral dosing, an improved time to symptom resolution and tolerability profile, with applicability to PAXLOVID-ineligible populations, and potential relevance to long-COVID prevention strategies." Iain Dukes MA DPhil, Chief Executive Officer.

Industry Context

The filing addresses critical threats from respiratory viral diseases, specifically influenza and COVID-19. The IND filing for tivoxavir marboxil aligns with government efforts (BARDA, HHS) to build a strategic national stockpile against potential future disease outbreaks, including bird flu (H5N1), indicating a focus on pandemic preparedness. Ratutrelvir's development targets a significant gap in COVID-19 treatment, particularly for PAXLOVID-ineligible patients, and aims to offer a differentiated profile against existing therapies like PAXLOVID by addressing issues such as viral rebound and adverse events, and potentially Long COVID. This positions Traws Pharma within the competitive antiviral market, seeking to capture market share by offering improved safety and efficacy profiles.

Comparison to Industry Standards

• Ratutrelvir demonstrated numerically superior time-to-sustained symptom alleviation (12 days) compared to PAXLOVID (14 days, p<0.014).
• Ratutrelvir showed no COVID-19 symptom or virologic rebound events, while one rebound event was observed in the PAXLOVID comparator arm shortly after completion of its standard 5-day dosing regimen.
• Ratutrelvir was well tolerated with fewer reported adverse events (mild dyspepsia in 7.6% of patients) compared to PAXLOVID (adverse events in 30% of patients, including dysgeusia, dizziness, and dyspepsia), consistent with prior clinical trial and real-world experience for PAXLOVID.
• Ratutrelvir's ritonavir-free administration avoids drug-drug interactions associated with ritonavir-boosted regimens like PAXLOVID, making it suitable for PAXLOVID-ineligible patients who often have elevated risk for severe disease.
• Tivoxavir marboxil is positioned as a potential best-in-class CAP-dependent endonuclease inhibitor, with potent in vitro activity against various influenza strains, including a human isolate of the highly pathogenic avian flu H5N1, and positive preclinical data across three animal species, supporting its potential for inclusion in strategic national stockpiles.

Stakeholder Impact

• Shareholders: Positive impact due to significant clinical progress and regulatory milestones, potentially increasing company valuation and future revenue streams.
• Patients (COVID-19): Improved treatment options, especially for those ineligible for PAXLOVID, with better tolerability and reduced risk of viral rebound and potentially Long COVID.
• Patients (Influenza): Potential for a new, effective single-dose treatment for seasonal and pandemic influenza, including bird flu.
• Healthcare Providers: New tools for managing COVID-19 and influenza, particularly for high-risk or difficult-to-treat patient populations.
• Government/Regulatory Bodies: Potential for a new therapeutic agent (TXM) to be included in national stockpiles, enhancing public health preparedness.

Next Steps

• Formal consideration of tivoxavir marboxil by BARDA for inclusion in the strategic national stockpile.
• Continued clinical evaluation of ratutrelvir in both acute COVID-19 and in studies designed to better understand its potential impact on longer-term outcomes (Long COVID).
• Confirmation of ratutrelvir's potential in dedicated clinical studies for Long COVID prevention.
• Full study enrollment for the ratutrelvir Phase 2 study (90 patients) expected in January 2026.
• Traws Pharma is actively seeking development and commercialization partners for its legacy clinical oncology programs, rigosertib and narazaciclib.

Key Dates

Recommendation

The filing details significant positive developments for Traws Pharma. The IND filing for tivoxavir marboxil for influenza, especially with its potential for inclusion in the strategic national stockpile, represents a major de-risking event and a substantial market opportunity. Even more compelling are the interim Phase 2 results for ratutrelvir, which demonstrate clear superiority over PAXLOVID in terms of faster symptom resolution, absence of viral rebound, and a significantly better tolerability profile, particularly for PAXLOVID-ineligible patients. This positions ratutrelvir as a potential best-in-class or next-generation treatment for COVID-19, addressing critical unmet needs and a multi-billion dollar market. These clinical and regulatory advancements are highly positive indicators for future commercial success and significantly enhance the company's valuation prospects, warranting a strong buy recommendation.

Keywords

Traws Pharma, TRAW, IND application, tivoxavir marboxil, TXM, influenza, COVID-19, ratutrelvir, PAXLOVID, Mpro inhibitor, 3CL protease inhibitor, CAP-dependent endonuclease inhibitor, FDA, BARDA, strategic national stockpile, antiviral, biopharmaceutical, clinical trial, Phase 2, H5N1, bird flu, ritonavir-free, drug development